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Objective: Personalized chemotherapy based on predictive biomarkers can maximize efficacy. However, tumor
tissue obtained at the time of initial diagnosis will not reflect genetic alterations observed at the time of disease
progression. We have examined whether plasma mRNA levels can be a surrogate for tumor levels in predicting
chemosensitivity.
Methods: In 150 gastric cancer patients, mRNA levels of BRCA1 and TS were assessed in plasma and paired tumor
tissue. The Mann-Whitney U-test was used to compare mRNA expression levels between tumor samples exhibiting
in vitro sensitivity or resistance to docetaxel and pemetrexed. All statistical tests were two-sided.
Results: There were significant correlations between plasma and tumor mRNA levels of BRCA1 (rho = 0.696,
P < 0.001) and TS (rho = 0.620, P < 0.001). BRCA1 levels in plasma (docetaxel-sensitive: 1.25; docetaxel-resistant: 0.50,
P < 0.001) and tumor (docetaxel-sensitive: 8.81; docetaxel-resistant: 4.88, P < 0.001) were positively associated with
docetaxel sensitivity. TS levels in plasma (pemetrexed-sensitive: 0.90; pemetrexed-resistant: 1.82, P < 0.001) and
tumor (pemetrexed-sensitive: 6.56; pemetrexed-resistant: 16.69, P < 0.001) were negatively associated with
pemetrexed sensitivity.
Conclusions: Plasma mRNA expression levels mirror those in the tumor and may have a promising role as
potential predictive biomarkers for chemotherapy.
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The standard first-line chemotherapy regimen for locally
advanced or metastatic gastric cancer is cisplatin or oxali-
platin combined with other drugs, including docetaxel and
pemetrexed [1,2]. However, median survival remains mea-
ger – around one year. No standard approach for second-
line therapy exists, although docetaxel has shown some
activity [3]. Personalized chemotherapy based on the
mRNA expression of predictive biomarkers could help to* Correspondence: baoruiliu@nju.edu.cn; rrosell@iconcologia.net
†Equal contributors
1The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School
of Nanjing University, Clinical Cancer Institute of Nanjing University, 321
Zhongshan Rd, Nanjing 210008, China
3Pangaea Biotech, Dexeus University Institute, Barcelona, Spain
Full list of author information is available at the end of the article
© 2014 Shen et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.maximize treatment efficacy and prolong survival in these
patients [3-8].
Breast cancer susceptibility gene 1 (BRCA1), an essen-
tial component in multiple DNA damage repair path-
ways and pathways involved in cellular responses to
microtubule damage, is considered to be a differential
modulator of survival with cisplatin and taxanes. Pre-
clinical and clinical studies have reported that BRCA1
level of tumor is associated with cisplatin and taxanes
chemosensitivity. Tumor with high expression of BRCA1
is 800-to-more than 1000-fold sensitive to docetaxel, but
10-1000-fold resistant to cisplatin [4]. We have previ-
ously observed that BRCA1 mRNA levels in effusions
were negatively associated with platinum sensitivity but
positively associated with docetaxel sensitivity in gastric
cancer patients [5]. These findings were validated inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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survival was 9.5 months in those with low BRCA1 levels
in primary tumor, 19.1 in those with intermediate levels,
and 25.8 months in those with high levels (P = 0.006) [3].
Pemetrexed is a new kind of water-soluble quinazoline
folate analogue, acts as a direct and specific thymidylate
synthase (TS) inhibitor. Low expression of thymidylate
synthase (TS) has been reported to be associated with re-
sponse to pemetrexed-based therapy in lung cancer [7,8].
Tumor tissue is the major source for biomarker exam-
ination at present. However, tumor tissue may at times
be insufficient for gene expression analysis. Moreover,
tumor tissue obtained at the time of initial diagnosis
may not reflect genetic alterations observed at the time
of disease progression [9], since metastatic and primary
tumors from the same patient can vary at genomic, epi-
genetic and transcriptomic levels [9-13]. Furthermore,
initial chemotherapy may itself alter gene expression
levels [14,15]. Circulating tumor cell-free nucleic acids
could thus be a useful, non-invasive tool for tracking
changes during the course of treatment [10], obviating
the need for a re-biopsy at the time of determining the
best treatment. In addition, it can be a useful surrogate
when only a small amount of tumor tissue is available.
Our previous experience in lung cancer demonstrated
that epidermal growth factor receptor (EGFR) mutations
in serum could be a good predictive marker for lung
cancer patients receiving EGFR tyrosine kinase inhibi-
tors [16]. In addition, plasma TS mRNA can be detected
non-invasively in blood before surgery and the expres-
sion level of plasma TS had great potential as predictive
biomarkers for raltitrexed sensitivity in gastric cancer
[17]. To date, however, little is known about the poten-
tial use of plasma mRNA for predicting chemosensitivity
of docetaxel and pemetrexed. Moreover, although RNA
released into circulation is stable [10,18], with currently
available methods, only a small amount of mRNA can
be obtained from plasma or serum, which limits both
the efficacy of mRNA extraction and the consistency of
mRNA assays [10].
In the present study, we adopted a practical and con-
venient method for plasma mRNA detection, based on
RNA purification and quantitative RT-PCR (qRT-PCR),
and used this method to examine whether plasma
mRNA levels can be a surrogate for tumor levels in pre-
dicting chemosensitivity – first in a pilot study of 40 pa-
tients and then in a total cohort of 150 patients.
Materials and methods
Patients
From October 2010 to July 2011, 150 freshly-removed gas-
tric tumors and paired blood samples from the same pa-
tients were obtained from the Department of Oncology
and General Surgery, Drum Tower Hospital, Nanjing,China. All the patients have not received any chemother-
apy before surgery. The fresh gastric tumors and blood
samples were kept at 4°C and sent to the laboratory within
15 minutes of collection.
The study was approved by the Institutional Ethics
Review Board of Drum Tower Hospital affiliated to the
Medical School of Nanjing University, and written in-
formed consent was provided by all patients. All animal
experiments were performed in accordance with the
Chinese Coordinating Committee on Cancer Research
Regulations for the Welfare of Animals and the Animal
Protection Law. All analyses, including drug sensitivity
testing, gene expression analysis and animal experiments,
were carried out by different investigators acting individu-
ally without knowledge of the results of the other analyses.
Study design
We first carried out a pilot study in 40 patients (Figure 1A).
For each tumor sample, sensitivity to docetaxel and peme-
trexed was examined in vitro by histoculture drug re-
sponse assay (HDRA) [19] and in vivo by xenografts in
immunodeficient mouse models [20] (Additional file 1:
Figure S1, A-B available online). In addition, both the
mouse xenografts and the original fresh tumor samples
were formalin-fixed and paraffin-embedded (FFPE) for the
analysis of BRCA1 and TS mRNA expression. BRCA1 and
TS expression was also analyzed in the paired blood
samples.
Based on the findings of the pilot study, we undertook
to validate our findings in the total cohort of 150 gastric
cancer patients (Figure 1B). In this cohort, the same pro-
cedures were carried out, with the exception of the
in vivo testing of chemosensitivity. The mRNA levels in
plasma and FFPE tumor tissues of BRCA1 and TS were
assessed and the Mann-Whitney U-test was used to
compare mRNA expression levels between tumor sam-
ples exhibiting in vitro sensitivity or resistance to doce-
taxel and pemetrexed.
For complete details of all methodology, see Additional
file 1, available online.
In vitro chemosensitivity in the pilot study and the total
cohort
Fresh tumor tissues were sent to the laboratory in 4°C
Hanks’ balanced salt solution with 1% penicillin/strepto-
mycin. Specimens were washed with Hanks’ balanced salt
solution twice and minced into small pieces of approxi-
mately 10 mg, which were then placed on prepared colla-
gen surfaces in 24-well microplates. Plates were incubated
for 7 days at 37°C in the presence of drugs dissolved with
RPMI 1640 medium containing 20% fetal calf serum and
kept in a humidified atmosphere containing 95% air–5%
CO2. Concentrations of drugs were 100 μg/ml for doce-
taxel [21], and 400 μg/ml for pemetrexed [7]. HDRA
Figure 1 Flow chart showing patient disposition and experiments performed. Pilot study in 40 patients (A) and total cohort of 150 gastric
cancer patients (B).
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colleagues [19] with slight modifications. The inhibition
rate was calculated by using the following formula: inhib-
ition rate (%) = (1-T/C) x 100, where T is the mean ab-
sorbance of treated tumor/weight and C is the mean
absorbance of control tumor/weight. All samples were
classified into sensitive and resistant groups using the
minimum P value method as modified by Lausen and
Schumacher [22].
In vivo chemosensitivity in the pilot study
Each freshly-removed surgical tumor tissue was cut into
pieces of 3 × 3 × 3mm3, which were transplanted within 30
minutes to 9-18 athymic immunodeficient mice, termed a
“panel”. In each panel, when the tumor grew to a size of
50-100 mm3, mice with xenografts were randomized to
treatment with docetaxel 15 mg/kg/d, ip or pemetrexed
20 mg/kg/d, ip or no treatment (control). Individual tumor
volumes (V) were calculated by the formula “V = (length ×
width × width) / 2” and compared to the values at the start
of treatment to obtain the relative tumor volume. Median
treated-to-control values of relative tumor volume weretermed “inhibition rate in vivo” and were used to assess
sensitivity to docetaxel or pemetrexed.
mRNA expression in the pilot study and the total cohort
Two milliliters of blood were collected in EDTA tubes be-
fore surgery, kept at 4°C and sent to the laboratory within
15 minutes. Total RNA from plasma was extracted with
TRIzol LS and chloroform, and purified with the PureLink
RNA Mini Kit (Ambion, Carlsbad, CA, USA). Total RNA
from FFPE tumor tissues was extracted in accordance
with a proprietary procedure (European patent number
EP1945764-B1). After RNA extraction and purification,
M-MLV Reverse Transcriptase Kit (Invitrogen, Carlsbad,
CA, USA) was used to generate cDNA for Q-PCR to de-
tect the expression of β-actin (ACTB – used as endogen-
ous control) and the genes examined. Each batch of
reaction included a positive control from commercial hu-
man lung and liver RNA (Stratagene, La Jolla, CA, USA)
as calibrators and negative controls without RNA and re-
verse transcriptase. Template cDNA was amplified with
specific primers and probes using Taqman Universal
Master Mix (Applied Biosystems, Foster City, CA, USA).
Table 1 Patient characteristics
Characteristic Pilot study Total cohort*
N = 40 N = 150
N (%) N (%)
Age, yr, median (range) 63 (40-83) 64 (29-84)
Sex
Male 31 (77.5) 110 (73.3)
Female 9 (22.5) 40 (26.7)
Tumor site
Distal stomach 12 (30.0) 57 (34.0)
Proximal stomach 19 (47.5) 62 (41.3)
Whole stomach 9 (22.5) 37 (24.7)
Stage
I 4 (10.0) 17 (11.3)
II 9 (22.5) 34 (22.7)
III 25 (62.5) 94 (62.7)
IV 2 (5.0) 5 (3.3)
Histological grade
1 0 3 (2.0)
2 8 (20.0) 31 (20.7)
3 22 (55.0) 71 (47.3)
Mixed 1–2 0 2 (1.3)
Mixed 2–3 10 (25.0) 43 (28.7)
Lymph node metastasis
No 9 (22.5) 35 (23.3)
Yes 31 (77.5) 115 (76.7)
*The total cohort consisted of the original 40 patients included in the pilot
study plus an additional 110 patients.
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lated according to the comparative Ct method. Final
results were determined by the formula mRNA ex-
pression level = 2-△△Ct [6,23] and were analyzed with
the Stratagene software.
Reproducibility and stability of the gene expression assay
in plasma
The reproducibility of the gene expression assay was
tested simultaneously with two methods. For the first
method, blood samples from five patients were collected
from the first day to the fifth day before surgery at the
same time each day. During this period, patients re-
ceived neither chemotherapy nor special treatment.
Gene expression levels (high/intermediate vs low) were
determined for each sample, and the percentage of iden-
tical results was calculated for each patient. For the sec-
ond method, blood was drawn once each from an
additional ten patients, and each sample was divided in
five aliquots. Gene expression levels (high/intermediate
vs low) were determined for each aliquot, and the per-
centage of identical results was calculated for each pa-
tient. The reproducibility rate was defined as the average
of all 15 percentages (5 patients from method one and
10 patients from method two).
In order to test the stability of the blood samples, dif-
ferent plasma aliquots of the same sample were prepared
under distinct conditions. Aliquots were incubated at
room temperature or on ice for 30 min, 1 h, 1.5 h or 2 h.
qRT-PCR was then performed, and raw ΔCt values of
different gene were compared with the standard protocol
(ΔCt = Ct gene-Ct ACTB ).
Statistical analyses
The Mann-Whitney U-test and the Kruskal-Wallis test
were used to test associations between mRNA levels and
clinical characteristics and between sensitivity to each
chemotherapeutic agent and clinical characteristics. The
Spearman rank correlation test was used to assess the
correlation between in vivo and in vitro inhibition rates
and between plasma and tumor mRNA expression
levels. The Mann-Whitney U-test was used to compare
mRNA expression levels between tumor samples exhi-
biting in vitro sensitivity or resistance to docetaxel and
pemetrexed. Receiver operating characteristics (ROC)
curves were constructed to assess sensitivity, specificity,
and respective areas under the curves (AUCs) with their
95% confidence intervals (CIs). We investigated the opti-
mized cut-off value for prediction by maximizing the
sum of sensitivity and specificity and minimizing the
overall error (square root of the sum [1-sensitivity]2 +
[1-specifi city]2), and by minimizing the distance of the
cut-off value to the top-left corner of the ROC curve
[24]. All statistical tests were two-sided, and significancewas set at P < 0.05 (two-sided). All analyses were per-
formed using SPSS, version 16.0.
Results
Characteristics of all patients are shown in Table 1. The
majority of patients were males (73.3%), and the pre-
dominant histology was adenocarcinoma. Ninety-four
(62.7%) patients had stage III disease. Lymph node me-
tastases were present in 115 (76.7%) patients.
The reproducibility of the plasma mRNA detection
was 92% for BRCA1, and 89% for TS. The mRNA ex-
pression levels were stable after room temperature or ice
incubation for 30 min, 1h, 1.5 h and 2 h (Additional file 1:
Figure S2, available online).
Pilot study
Sensitivity to docetaxel and pemetrexed was successfully
assessed in the 40 fresh tumor samples by HDRA. Eleven
panels of immunodeficient mice (9-18 mice per panel, 148
mice in total) with human-derived xenografts were suc-
cessfully established from all 40 surgical specimens for
Figure 2 Correlations between plasma and tumor mRNA expression levels of (A) BRCA1 and (B) TS in 150 gastric cancer patients.
There was a significant correlation between plasma and tumor mRNA expression levels of both genes (P < 0.001, respectively).
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relation test showed a significant correlation between
in vitro and in vivo inhibition rates for docetaxel (rho =
0.900, P < 0.001) and pemetrexed (rho = 0.836, P < 0.001)
(Additional file 1: Figure S3, A-B, available online).
BRCA1 mRNA levels were successfully assessed in all
40 tumor samples, in 32 paired blood samples, and in 10
panels of mouse models, while TS mRNA levels were suc-
cessfully assessed in all 40 tumor samples, all 40 blood sam-
ples, and in 9 panels of mouse models. The Spearman rankFigure 3 In vitro chemosensitivity associated with plasma and tumor
BRCA1 levels in plasma (A) and tumor (B) were higher in the docetaxel-sen
and tumor (D) were lower in the pemetrexed-sensitive than in the pemetr
The whiskers of box plots: SE, 95% CI.correlation test showed a correlation between plasma and
tumor mRNA levels of BRCA1 (rho = 0.647, P < 0.001) and
between plasma and tumor levels of TS (rho = 0.615,
P < 0.001) (Additional file 1: Figure S4, A-B, available
online). Both plasma and tumor BRCA1 levels were
correlated with docetaxel sensitivity (rho = 0.492, P = 0.004
and rho = 0.527, P < 0.001, respectively), and both plasma
and tumor TS levels correlated with pemetrexed resistance
(rho = -0.627, P < 0.001 and rho = -0.443, P = 0.004, respect-
ively, Spearman rank correlation test) (Additional file 1:expression levels of BRCA1and TS in 150 gastric cancer patients.
sitive than in the docetaxel -resistant group. TS levels in plasma (C)
exed-resistant group. The lines inside the boxes denoted the medians.
Table 2 Sensitivity and specificity of plasma and tumor gene expression levels for the prediction of chemosensitivity
Gene expression Chemotherapeutic agents N Optimal cut-off Sensitivity Specificity AUC (95% CI) P
Plasma
BRCA1 Docetaxel 123 0.76 63% 90% 0.77 (0.67-0.87) <0.001
TS Pemetrexed 136 1.01 71% 78% 0.78 (0.69-0.87) <0.001
Tumor
BRCA1 Docetaxel 123 6.09 70% 79% 0.75 (0.66-0.84) <0.001
TS Pemetrexed 136 8.08 78% 79% 0.83 (0.76-0.90) <0.001
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higher in the docetaxel-sensitive than in the docetaxel-
resistant mouse models (11.26 vs 2.63; P < 0.001), while TS
levels were higher in the pemetrexed-resistant than in the
pemetrexed-sensitive mice (3.34 vs 7.27; P = 0.013, Mann-
Whitney U-test) (Additional file 1: Figure S6, A-B, avail-
able online).
Total cohort
BRCA1 and TS mRNA expression was successfully assessed
in tumor tissues from all 150 patients. The detection rate in
plasma were 82.00% for BRCA1 and 90.67% for TS. The
mean mRNA levels in plasma and tumor are shown in
Additional file 1: Table S1, available online. There was no
significant association between clinical characteristics and
the mRNA expression levels of BRCA1 or TS (P > 0.05).
There was a positive correlation between plasma and
tumor mRNA levels of BRCA1 (rho = 0.696, P < 0.001)
and TS (rho = 0.620, P < 0.001, Spearman rank correlation
test) (Figure 2A-B). No differences in baseline characteris-
tics were observed according to plasma mRNA levels,
tumor mRNA levels, or in vitro chemosensitivity.
BRCA1 levels in plasma (docetaxel-sensitive: 1.25;
docetaxel-resistant: 0.50, P < 0.001) and tumor (docetaxel-
sensitive: 8.81; docetaxel-resistant: 4.88, P < 0.001) were
positively associated with docetaxel sensitivity. BRCA1
levels in plasma and tumor were higher in the docetaxel-Figure 4 ROC curves showing the sensitivity and specificity of plasma
(A) BRCA1 and docetaxel (n = 123); (B) TS and pemetrexed (n = 136).sensitive than in the docetaxel -resistant group. TS levels in
plasma (pemetrexed-sensitive: 0.90; pemetrexed-resistant:
1.82, P < 0.001) and tumor (pemetrexed-sensitive: 6.56;
pemetrexed-resistant: 16.69, P < 0.001) were negatively as-
sociated with pemetrexed sensitivity. TS levels in plasma
and tumor were lower in the pemetrexed-sensitive than in
the pemetrexed-resistant group. (Figure 3A-D, Mann-
Whitney U-test).
Sensitivity in predicting chemosensitivity ranged from
63% to 71% for plasma and from 70% to 78% for tumor
mRNA. Specificity ranged from 78% to 90% for plasma
and 79% for tumor mRNA (Table 2, Figure 4).
Discussion
In the present study, BRCA1 and TS mRNA levels in
plasma were correlated with levels in paired FFPE tumor
tissue. BRCA1 and TS mRNA levels in both plasma and
tumor were associated with in vitro chemosensitivity of
freshly explanted gastric cancer. Moreover, plasma mRNA
levels showed considerable sensitivity and specificity in
predicting chemosensitivity. Taken together, these findings
indicate that plasma mRNA mirrors tumor mRNA and
may prove a useful tool for predicting chemosensitivity.
The method we established to detect plasma mRNA,
based on RNA enrichment by purification column, enables
more accurate, sensitive and reproducible detection, easier
handling and faster results [10,25], making it feasible forand tumor gene expression in predicting chemosensitivity.
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[25]. However, the contamination of mRNA by non-tumor
sources, such as activated lymphocytes, stromal cells or
circulating tumor cells, cannot be ruled out [10,26,27] and
may partially explain why the correlation between plasma
and tumor expression was less than perfect. Moreover,
tumor heterogeneity may account for some variability as
well. Specificity ranged from 78% to 90% for plasma while
79% for tumor. The less perfect specificity in tumor may
well be due to the heterogeneity of the tumor tissue itself,
which lends further support to the use of plasma mRNA
for predicting sensitivity.
Recent studies have examined the cell-free mRNA ex-
pression of several genes, including TS [28], β-catenin
[29], hTERT [26,30,31], CK19 [32,33], MUC1 [34], CXCR4
[35], Bmi-1 [35], Her-2 [36] and DKK1 [24], these studies
have focused on the use of cell-free mRNA for early diag-
nosis, tumor staging and disease monitoring. In contrast,
to the best of our knowledge, the present study is the first
to examine the potential role of plasma mRNA for pre-
dicting docetaxel and pemetrexed chemosensitivity of
solid tumors. Our findings suggest a promising role for
plasma mRNA expression as a predictive biomarker in
gastric cancer and provide evidence for the use of plasma
mRNA in selecting chemotherapy for patients without the
need for re-biopsy at the time of disease progression. In
addition, plasma mRNA may also prove useful for moni-
toring patients being treated in the neoadjuvant or adju-
vant setting. The treatment plan for these patients could
be generated according to their mRNA chemosensitivity
profile. For example, gastric cancer patients with low levels
of plasma TS mRNA can be treated with pemetrexed-
based chemotherapy, while those with high levels of plasma
BRCA1 could benefit from treatment with docetaxel.
Nonetheless, we should note that our study may have
some limitations. The current study is based on patients,
who are therapy-naïve. By collecting their plasma before
surgery and tumors right after surgery, we could demon-
strated the plasma mRNA value for monitoring patients
being treated in the neoadjuvant or adjuvant setting.
Then, the detection sensitivity and value of picking up
circulating mRNA from early metastases especially for
patients reserving second line chemotherapy is still un-
clear. Now we are also carrying out further study on pa-
tients with metastases and cannot receiving surgery or
to receive second line chemotherapy. We will have the
latest results in the near future which will contain the
content mentioned above.
Conclusion
In conclusion, plasma mRNA expression levels of BRCA1
and TS could mirror those in the tumor and may have a
promising role as potential predictive biomarkers for do-
cetaxel and peretrexed in gastric cancer. These findingsare preliminary and only suggestive at this point, and each
of these paired biomarker-chemotherapy hypotheses needs
to be validated before being used in routine daily clinical
practice. A clinical trial is currently being designed in
order to validate the role of customizing treatment based
on the plasma mRNA expression of BRCA1 and TS.
Additional file
Additional file 1: Supplementary Methods. Table S1. Mean mRNA levels
in plasma and tumor. Figure S1. Original tumor and paired mouse xenografts.
(A) The morphology of the original tumor diagnosed as adenocarcinoma with
partial mucous cell carcinoma. (B) Paired xenografts in immunodeficient mice,
confirmed by hematoxylin-eosin staining. There were no significant
morphological differences between the original tumor sample and the paired
xenografts in the mouse models. Figure S2. Validation of the stability of
plasma mRNA. Plasma mRNA levels of all the genes were stable after being
subjected to various conditions. Figure S3. Correlations between in vitro and
in vivo inhibition rates for (A) docetaxel and (B) pemetrexed in the pilot study.
Figure S4. Correlation between plasma and tumor mRNA expression of
(A) BRCA1 (n = 32) and (B) TS (n = 40) in the pilot study. Figure S5. Correlations
between mRNA expression levels and in vitro chemosensitivity in the pilot
study. (A) Tumor BRCA1 and docetaxel sensitivity; (B) plasma BRCA1 and
docetaxel sensitivity; (C) tumor TS and pemetrexed sensitivity; and (D) plasma
TS and pemetrexed sensitivity. Figure S6.mRNA expression levels and in vivo
chemosensitivity. Using a tumor inhibition cut-off of 50%, mouse models were
divided into (A) docetaxel-sensitive and docetaxel-resistant subgroups and (B)
pemetrexed-sensitive and pemetrexed-resistant subgroups. BRCA1 mRNA levels
(dots) were higher in the docetaxel-sensitive group than in the docetaxel-
resistant group (P < 0.001), and TS levels (dots) were higher in the pemetrexed-
resistant group than in the pemetrexed-sensitive group (P = 0.013).
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